Published On : September 2026
A basic polymorph screen and a comprehensive solid state characterization package can carry the same service label yet differ enormously in analytical depth, a distinction that matters more to a program timeline than the label itself within the pharmaceutical solid form development market.
The number and combination of analytical techniques applied, not the service category name on a proposal, determines how quickly a molecule's solid form landscape can be genuinely mapped and how much confidence a development team can place in the result.
A screening program that stops at basic X-ray powder diffraction and differential scanning calorimetry produces a much shallower picture than one that adds solid-state nuclear magnetic resonance and Raman spectroscopy to confirm form identity under varying humidity and temperature conditions.
Program teams evaluating a provider's screening capability should ask which specific techniques are included by default versus offered as a paid add-on, since a proposal that looks similar on price can differ substantially in the analytical confidence it actually delivers.
The consequence of underestimating this distinction shows up later rather than immediately: a program that accepts a shallow screen to save time or cost often discovers the gap only when a later-stage stability or regulatory review surfaces a form-related question the original screening data cannot answer.
Program teams new to outsourcing solid form work sometimes assume a standardized screening package exists across providers, when in practice the specific technique combination, number of conditions tested and turnaround commitment vary meaningfully enough between providers that a direct proposal-to-proposal comparison requires careful reading beyond the headline service name.
Cost comparisons across providers are similarly easy to misread on a surface level: a lower quoted price for a nominally equivalent screen sometimes reflects fewer crystallization conditions tested or a narrower analytical technique set, a tradeoff a program team should weigh deliberately rather than default toward the lowest headline number.
X-ray powder diffraction remains the foundational technique for confirming crystalline form identity, distinguishing one polymorph from another based on each form's distinct diffraction pattern.
Differential scanning calorimetry and thermogravimetric analysis together characterize a solid form's thermal behavior, revealing melting point, polymorphic transitions and any solvate or hydrate content that would otherwise go undetected by diffraction alone.
Raman spectroscopy and Fourier-transform infrared spectroscopy provide complementary molecular-level confirmation, particularly valuable for distinguishing closely related polymorphs or confirming co-crystal formation where diffraction data alone can be ambiguous.
Solid-state nuclear magnetic resonance offers the deepest structural confirmation available among routine techniques, capable of resolving subtle polymorphic differences that thermal and diffraction methods sometimes cannot separate on their own, though its cost and instrument availability make it a technique reserved for cases where the added confidence justifies the expense.
Instrument access, not just technique knowledge, shapes which providers can realistically offer the full characterization suite, since solid-state nuclear magnetic resonance in particular requires a dedicated, high-field instrument that represents a significant capital commitment few smaller labs maintain in-house.
The order in which these techniques are applied also matters for efficiency: a well-designed screening program typically uses faster, lower-cost techniques such as XRPD and DSC to narrow a large set of candidate forms before committing the time and expense of SSNMR confirmation to only the most promising few.
Turnaround expectations for each technique also differ, with XRPD and DSC results often available within days while SSNMR queue times can extend to several weeks at some providers.
Data interpretation, not just data generation, is where genuine analytical expertise shows: two providers running identical XRPD scans can reach different conclusions about whether an observed pattern represents a genuinely new polymorph or a minor variant of an already-identified form, a judgment call that experience meaningfully improves.
Salt screening evaluates which counter-ion, if any, produces the most favorable solubility, stability and manufacturability profile for a given active ingredient, a decision that shapes nearly every downstream formulation choice.
Polymorph screening systematically explores the crystalline forms a molecule can adopt under different crystallization conditions, since an unstable or undesirable polymorph discovered after formulation work has already begun can force a costly restart.
A screening program's design typically anticipates the downstream crystallization process development work that follows, since the form selected during screening becomes the target the scale-up process must reliably reproduce.
High-throughput screening platforms have shortened typical screening timelines meaningfully over the past several years, running dozens to hundreds of crystallization conditions in parallel rather than the sequential, manually-driven approach earlier screening programs relied on.
The number of crystallization conditions tested in a screening campaign directly affects confidence in the result, since a form landscape mapped across only a handful of conditions carries real risk of missing a more stable or more soluble form that a broader screen would have found.
Documentation practices during screening also affect downstream value: a provider that records not just successful outcomes but also the full range of conditions tested, including those that did not produce a usable form, leaves a program with a more complete record to reference if a form-related question arises much later in development.
Salt selection decisions carry consequences well beyond the immediate solubility and stability profile, since the counter-ion chosen also affects dosage form options, manufacturing process compatibility and, in some cases, the ultimate patent landscape a program can pursue.
|
TECHNOLOGY WATCH Providers are increasingly pairing high-throughput screening platforms with machine-learning-assisted crystallization outcome prediction, narrowing the experimental space a screening program needs to physically test before converging on a viable form. |
Co-crystal development offers a path to modifying a molecule's physical properties without altering its covalent structure, combining an active ingredient with a pharmaceutically acceptable co-former to improve solubility or stability where a conventional salt form is unavailable or unsuitable.
Amorphous solid dispersion development takes a different approach entirely, dispersing a molecule in a non-crystalline, molecularly disordered state within a polymer matrix, a technique increasingly relied upon for poorly soluble compounds where no crystalline form offers adequate bioavailability.
Both approaches demand specialized stability testing beyond what a conventional crystalline form requires, since an amorphous dispersion in particular carries an inherent thermodynamic drive to recrystallize over time, a risk that must be characterized and managed through formulation design.
Selecting between a co-crystal and an amorphous dispersion approach, rather than defaulting to whichever a given provider specializes in, depends heavily on the specific solubility challenge a molecule presents and the manufacturing platform ultimately intended for commercial production.
Regulatory precedent for both approaches has matured considerably over the past decade, with multiple approved products now on the market using each technique, giving sponsors more confidence that either path is viable for a regulatory filing rather than an unusually novel approach an agency has not previously reviewed.
The manufacturing implications of each approach also diverge meaningfully: a co-crystal generally integrates into a conventional crystallization and formulation process with comparatively modest process changes, while an amorphous dispersion typically requires specialized manufacturing equipment such as hot-melt extrusion or spray drying that not every downstream manufacturing partner maintains.
Scale-up feasibility for each approach should factor into the earliest selection decision rather than being addressed only once a specific form has already been chosen.
Particle engineering and micronization services control particle size, shape and surface properties independent of the underlying crystal form itself, a capability that providers offering high-throughput screening, detailed in our overview of which providers offer high-throughput screening, increasingly bundle alongside their core screening services.
Micronization reduces particle size to improve dissolution rate and content uniformity, particularly important for low-dose or poorly soluble formulations where particle size directly affects how consistently an active ingredient distributes within a finished dosage form.
Advanced particle engineering techniques, including spray drying and controlled precipitation, can simultaneously influence particle size, morphology and even amorphous versus crystalline character, making this service category one where the line between analytical screening and process development genuinely blurs.
Programs working with high potency or cytotoxic APIs face additional particle engineering considerations around containment during size reduction, a requirement that narrows the field of providers capable of handling the work safely to those with dedicated containment infrastructure.
Choosing between micronization and a more advanced particle engineering technique such as spray drying often comes down to whether particle size reduction alone solves the underlying bioavailability challenge, or whether a more fundamental change to particle morphology or amorphous character is genuinely required.
Equipment cleaning and cross-contamination controls take on particular importance for particle engineering work involving multiple client molecules sharing production equipment, an operational consideration that shapes which facilities a sponsor working with a sensitive or high-value molecule is comfortable selecting.
The core techniques are X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis, Raman spectroscopy, Fourier-transform infrared spectroscopy and solid-state nuclear magnetic resonance, each contributing a different layer of structural and thermal confirmation.
Timelines vary by screening scope and technique combination, but high-throughput platforms running dozens to hundreds of parallel crystallization conditions have shortened typical screening timelines meaningfully compared with earlier sequential approaches.
The choice depends on the specific solubility challenge a molecule presents and the intended commercial manufacturing platform; co-crystal development modifies physical properties while preserving crystalline structure, while amorphous dispersion addresses cases where no crystalline form offers adequate bioavailability.
Particle size and morphology directly affect dissolution rate and content uniformity, particularly for low-dose or poorly soluble formulations, making particle engineering a distinct consideration from crystal form selection alone.
High potency and cytotoxic API programs require dedicated containment infrastructure during particle size reduction and handling, narrowing the field of providers capable of safely performing this specific work.